18F-Fluorocholine for the Detection of Parathyroid Adenomas

• Status: Completed
• Trial end date: 2021-05-31
• Target enrollment: 0
• Participant gender: All

Summary

The investigators are studying the ability of F18 labeled fluorocholine PET to localize parathyroid adenomas in patients with hyperparathyroidism prior to surgery.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Thomas Hope; University of California, San Francisco
• Treatments: Choline

Criteria

Inclusion Criteria:

• Biochemically proven hyperparathyroidism and an indication for surgery

• Age >= 13 years old

• Karnofsky performance status of > 50 (or Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO) equivalent).

• Ability to understand a written informed consent document, and the willingness to sign it.

Exclusion Criteria:

• Patients exceeding the weight limitations of the scanner or are not able to enter the bore of the PET scanner due to BMI.

• Inability to lie still for the entire imaging time (e.g. cough, severe arthritis, etc.).

• Inability to complete the needed investigational due to other reasons (severe claustrophobia, radiation phobia, etc.).

• Pregnancy.